Pharma majors Sanofi and GSK join hands to develop vaccine for COVID-19
World | Apr 14, 2020, 08:16 PM ISTAs per the partnership, France-based Sanofi will contribute its S-protein COVID-19 antigen, which is based on recombinant DNA technology. London-headquartered GSK, on the other hand, will contribute its proven pandemic adjuvant technology.